Your session is about to expire
← Back to Search
CRISPR-Edited TIL Therapy for Gastrointestinal Cancer
Study Summary
This trial is testing whether genetically-engineered TIL cells, which have been edited with CRISPR to turn off the CISH checkpoint, are safe and effective at treating GI cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: CISH CRISPR TIL / Phase I Arm
- Group 2: CISH CRISPR TIL / Phase II Arm
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What benefits does Tumor-Infiltrating Lymphocytes (TIL) provide for patients?
"TIL therapy can be utilized to fight multiple sclerosis, leukemia, myelocytic and acute retinoblastoma."
Who is the ideal population to recruit for this experiment?
"This medical trial is recruiting around 20 people who are within the ages of 18 and 70, as well as those suffering from gastrointestinal neoplasms."
Can geriatrics partake in this research endeavor?
"As specified by the inclusion criteria, only patients between 18 and 70 years of age can join this trial. However, there are 376 trials available for minors and 2512 studies suitable for senior citizens."
Are there available vacancies for participants in this experiment?
"According to the data hosted on clinicaltrials.gov, this medical trial is still recruiting participants since it was initially posted May 15th 2020 with an update on September 30th 2022."
Could you provide an overview of the clinical trials that have tested Tumor-Infiltrating Lymphocytes (TIL) as a treatment?
"Presently, there are 913 clinical studies being conducted on Tumor-Infiltrating Lymphocytes (TIL), with 163 of those in the advanced Phase 3. The majority are found within Philadelphia, Pennsylvania, though a total of 28673 locations have trials running for this therapy."
What is the current estimated enrollment of this medical trial?
"Affirmative. According to information hosted on clinicaltrials.gov, this trial is currently seeking participants and was first posted on May 15th 2020. It requires 20 patients from one medical centre for enrollment before September 30th 2022."
Share this study with friends
Copy Link
Messenger